The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
Identifieur interne : 000348 ( Main/Exploration ); précédent : 000347; suivant : 000349The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
Auteurs : S. Xie ; M. A. Furjanic [États-Unis] ; J. J. Ferrara [États-Unis] ; N. R. Mcandrew [États-Unis] ; E. L. Ardino [États-Unis] ; A. Ngondara [États-Unis] ; Y. Bernstein [États-Unis] ; K. J. Thomas [États-Unis] ; E. Kim [États-Unis] ; J. M. Walker [États-Unis] ; S. Nagar [États-Unis] ; S. J. Ward [États-Unis] ; R. B. Raffa [États-Unis]Source :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 2007-06.
English descriptors
- KwdEn :
Abstract
There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over‐activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB1 (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.
Url:
DOI: 10.1111/j.1365-2710.2007.00817.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000375
- to stream Istex, to step Curation: 000219
- to stream Istex, to step Checkpoint: 000130
- to stream Main, to step Merge: 000349
- to stream Main, to step Curation: 000348
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title><author><name sortKey="Xie, S" sort="Xie, S" uniqKey="Xie S" first="S." last="Xie">S. Xie</name></author><author><name sortKey="Furjanic, M A" sort="Furjanic, M A" uniqKey="Furjanic M" first="M. A." last="Furjanic">M. A. Furjanic</name></author><author><name sortKey="Ferrara, J J" sort="Ferrara, J J" uniqKey="Ferrara J" first="J. J." last="Ferrara">J. J. Ferrara</name></author><author><name sortKey="Mcandrew, N R" sort="Mcandrew, N R" uniqKey="Mcandrew N" first="N. R." last="Mcandrew">N. R. Mcandrew</name></author><author><name sortKey="Ardino, E L" sort="Ardino, E L" uniqKey="Ardino E" first="E. L." last="Ardino">E. L. Ardino</name></author><author><name sortKey="Ngondara, A" sort="Ngondara, A" uniqKey="Ngondara A" first="A." last="Ngondara">A. Ngondara</name></author><author><name sortKey="Bernstein, Y" sort="Bernstein, Y" uniqKey="Bernstein Y" first="Y." last="Bernstein">Y. Bernstein</name></author><author><name sortKey="Thomas, K J" sort="Thomas, K J" uniqKey="Thomas K" first="K. J." last="Thomas">K. J. Thomas</name></author><author><name sortKey="Kim, E" sort="Kim, E" uniqKey="Kim E" first="E." last="Kim">E. Kim</name></author><author><name sortKey="Walker, J M" sort="Walker, J M" uniqKey="Walker J" first="J. M." last="Walker">J. M. Walker</name></author><author><name sortKey="Nagar, S" sort="Nagar, S" uniqKey="Nagar S" first="S." last="Nagar">S. Nagar</name></author><author><name sortKey="Ward, S J" sort="Ward, S J" uniqKey="Ward S" first="S. J." last="Ward">S. J. Ward</name></author><author><name sortKey="Raffa, R B" sort="Raffa, R B" uniqKey="Raffa R" first="R. B." last="Raffa">R. B. Raffa</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1365-2710.2007.00817.x</idno><idno type="url">https://api.istex.fr/document/2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000375</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000375</idno><idno type="wicri:Area/Istex/Curation">000219</idno><idno type="wicri:Area/Istex/Checkpoint">000130</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000130</idno><idno type="wicri:doubleKey">0269-4727:2007:Xie S:the:endocannabinoid:system</idno><idno type="wicri:Area/Main/Merge">000349</idno><idno type="wicri:Area/Main/Curation">000348</idno><idno type="wicri:Area/Main/Exploration">000348</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title><author><name sortKey="Xie, S" sort="Xie, S" uniqKey="Xie S" first="S." last="Xie">S. Xie</name></author><author><name sortKey="Furjanic, M A" sort="Furjanic, M A" uniqKey="Furjanic M" first="M. A." last="Furjanic">M. A. Furjanic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Ferrara, J J" sort="Ferrara, J J" uniqKey="Ferrara J" first="J. J." last="Ferrara">J. J. Ferrara</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Mcandrew, N R" sort="Mcandrew, N R" uniqKey="Mcandrew N" first="N. R." last="Mcandrew">N. R. Mcandrew</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Ardino, E L" sort="Ardino, E L" uniqKey="Ardino E" first="E. L." last="Ardino">E. L. Ardino</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Ngondara, A" sort="Ngondara, A" uniqKey="Ngondara A" first="A." last="Ngondara">A. Ngondara</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Bernstein, Y" sort="Bernstein, Y" uniqKey="Bernstein Y" first="Y." last="Bernstein">Y. Bernstein</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Thomas, K J" sort="Thomas, K J" uniqKey="Thomas K" first="K. J." last="Thomas">K. J. Thomas</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Kim, E" sort="Kim, E" uniqKey="Kim E" first="E." last="Kim">E. Kim</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Walker, J M" sort="Walker, J M" uniqKey="Walker J" first="J. M." last="Walker">J. M. Walker</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Nagar, S" sort="Nagar, S" uniqKey="Nagar S" first="S." last="Nagar">S. Nagar</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Ward, S J" sort="Ward, S J" uniqKey="Ward S" first="S. J." last="Ward">S. J. Ward</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Raffa, R B" sort="Raffa, R B" uniqKey="Raffa R" first="R. B." last="Raffa">R. B. Raffa</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Temple University School of Pharmacy, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Clinical Pharmacy and Therapeutics</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-06">2007-06</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="209">209</biblScope><biblScope unit="page" to="231">231</biblScope></imprint><idno type="ISSN">0269-4727</idno></series><idno type="istex">2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332</idno><idno type="DOI">10.1111/j.1365-2710.2007.00817.x</idno><idno type="ArticleID">JCPT817</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CB1 receptor</term><term>cannabinoid</term><term>obesity</term><term>rimonabant</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over‐activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB1 (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><noCountry><name sortKey="Xie, S" sort="Xie, S" uniqKey="Xie S" first="S." last="Xie">S. Xie</name></noCountry><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Furjanic, M A" sort="Furjanic, M A" uniqKey="Furjanic M" first="M. A." last="Furjanic">M. A. Furjanic</name></region><name sortKey="Ardino, E L" sort="Ardino, E L" uniqKey="Ardino E" first="E. L." last="Ardino">E. L. Ardino</name><name sortKey="Bernstein, Y" sort="Bernstein, Y" uniqKey="Bernstein Y" first="Y." last="Bernstein">Y. Bernstein</name><name sortKey="Ferrara, J J" sort="Ferrara, J J" uniqKey="Ferrara J" first="J. J." last="Ferrara">J. J. Ferrara</name><name sortKey="Kim, E" sort="Kim, E" uniqKey="Kim E" first="E." last="Kim">E. Kim</name><name sortKey="Mcandrew, N R" sort="Mcandrew, N R" uniqKey="Mcandrew N" first="N. R." last="Mcandrew">N. R. Mcandrew</name><name sortKey="Nagar, S" sort="Nagar, S" uniqKey="Nagar S" first="S." last="Nagar">S. Nagar</name><name sortKey="Ngondara, A" sort="Ngondara, A" uniqKey="Ngondara A" first="A." last="Ngondara">A. Ngondara</name><name sortKey="Raffa, R B" sort="Raffa, R B" uniqKey="Raffa R" first="R. B." last="Raffa">R. B. Raffa</name><name sortKey="Thomas, K J" sort="Thomas, K J" uniqKey="Thomas K" first="K. J." last="Thomas">K. J. Thomas</name><name sortKey="Walker, J M" sort="Walker, J M" uniqKey="Walker J" first="J. M." last="Walker">J. M. Walker</name><name sortKey="Ward, S J" sort="Ward, S J" uniqKey="Ward S" first="S. J." last="Ward">S. J. Ward</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/DanceTherParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000348 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000348 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= DanceTherParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332
|texte= The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
}}
| This area was generated with Dilib version V0.6.35. |  |